ABUS

Arbutus Biopharma develops therapeutic candidates focused on chronic hepatitis B infection, aiming to create finite treatments that reduce viral burden while minimizing patient stigma and improving long-term outcomes. The organization is pursuing multiple patent infringement lawsuits against Pfizer/BioNTech, Moderna, and the United States, with settlement proceeds from Moderna potentially funding a shareholder capital return. Arbutus appears to be in clinical development stage, with ongoing clinical trials and third-party development collaborations underway.

Pipeline

Catalyst Calendar